Found: 48
Select item for more details and to access through your institution.
Effects of Image Characteristics on Performance of Tumor Delineation Methods: A Test--Retest Assessment.
- Published in:
- Journal of Nuclear Medicine, 2011, v. 52, n. 10, p. 1550, doi. 10.2967/jnumed.111.088914
- By:
- Publication type:
- Article
Monitoring Response to Antiangiogenic Therapy in Non--Small Cell Lung Cancer Using Imaging Markers Derived from PET and Dynamic Contrast-Enhanced MRI.
- Published in:
- Journal of Nuclear Medicine, 2011, v. 52, n. 1, p. 48, doi. 10.2967/jnumed.110.078261
- By:
- Publication type:
- Article
Repeatability of Metabolically Active Volume Measurements with <sup>18</sup>F-FDG and <sup>18</sup>F-FLT PET in Non--Small Cell Lung Cancer.
- Published in:
- Journal of Nuclear Medicine, 2010, v. 51, n. 12, p. 1870, doi. 10.2967/jnumed.110.077255
- By:
- Publication type:
- Article
Reproducibility of Tumor Perfusion Measurements Using <sup>15</sup>O-Labeled Water and PET.
- Published in:
- Journal of Nuclear Medicine, 2008, v. 49, n. 11, p. 1763, doi. 10.2967/jnumed.108.053454
- By:
- Publication type:
- Article
Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.
- Published in:
- Pharmaceutical Research, 2022, v. 39, n. 10, p. 2507, doi. 10.1007/s11095-022-03355-2
- By:
- Publication type:
- Article
Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.
- Published in:
- Nature Protocols, 2024, v. 19, n. 3, p. 700, doi. 10.1038/s41596-023-00933-5
- By:
- Publication type:
- Article
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262473
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262473
- By:
- Publication type:
- Article
First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small- cell lung cancer . .
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262473
- By:
- Publication type:
- Article
First-in-human study of<sup> 89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262473
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
Quantification of PD-L1 expression with [<sup>18</sup>F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD‐L1 expression with [ <sup>18</sup>F]BMS‐986192 PET/CT in patients with advanced stage non‐small‐cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD‐L1 expression with [<sup>18</sup>F]BMS‐986192 PET/CT in patients with advanced stage non‐small‐cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD‐L1 expression with [<sup>18</sup>F]BMS‐986192 PET/CT in patients with advanced stage non‐small‐cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 8, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD-L1 expression with [<sup>18</sup>F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD‐L1 expression with [ 18F]BMS‐986192 PET/CT in patients with advanced stage non‐small‐cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD-L1 expression with [<sup>18</sup>F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 4, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Quantification of PD‐L1 expression with [<sup>18</sup>F]BMS‐986192 PET/CT in patients with advanced stage non‐small‐cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 3, p. 1, doi. 10.2967/jnumed.119.240895
- By:
- Publication type:
- Article
Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with <sup>18</sup>F-Fluoroazomycin Arabinoside and <sup>15</sup>O-H<sub>2</sub>O PET.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 4, p. 530, doi. 10.2967/jnumed.115.166579
- By:
- Publication type:
- Article
Repeatability of <sup>18</sup>F-FDG Uptake Measurements in Tumors: A Metaanalysis.
- Published in:
- Journal of Nuclear Medicine, 2012, v. 53, n. 5, p. 701, doi. 10.2967/jnumed.111.095299
- By:
- Publication type:
- Article
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
- Published in:
- Oncologist, 2021, v. 26, n. 8, p. e1347, doi. 10.1002/onco.13580
- By:
- Publication type:
- Article
Use of H<sub>2</sub><sup>15</sup>O-PET and DCE-MRI to Measure Tumor Blood Flow.
- Published in:
- Oncologist, 2008, v. 13, n. 6, p. 631, doi. 10.1634/theoncologist.2007-0235
- By:
- Publication type:
- Article
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 6, p. 601, doi. 10.1016/j.cllc.2021.06.006
- By:
- Publication type:
- Article
Relationship between Biodistribution and Tracer Kinetics of 11 C-Erlotinib, 18 F-Afatinib and 11 C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 4, p. 883, doi. 10.3390/diagnostics12040883
- By:
- Publication type:
- Article
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1136221
- By:
- Publication type:
- Article
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 5, p. 683, doi. 10.1002/cncr.35090
- By:
- Publication type:
- Article
Feasibility of whole‐genome sequencing‐based tumor diagnostics in routine pathology practice.
- Published in:
- Journal of Pathology, 2022, v. 258, n. 2, p. 179, doi. 10.1002/path.5988
- By:
- Publication type:
- Article
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 1, p. 46, doi. 10.1177/1758834016670555
- By:
- Publication type:
- Article
Reproducibility of quantitative <sup>18</sup>F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2009, v. 36, n. 3, p. 389, doi. 10.1007/s00259-008-0960-5
- By:
- Publication type:
- Article
Repeatability of [<sup>18</sup>F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients.
- Published in:
- EJNMMI Research, 2019, v. 9, n. 1, p. 1, doi. 10.1186/s13550-019-0481-1
- By:
- Publication type:
- Article
89 Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs.
- Published in:
- Cancers, 2023, v. 15, n. 23, p. 5546, doi. 10.3390/cancers15235546
- By:
- Publication type:
- Article
Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy.
- Published in:
- Cancers, 2021, v. 13, n. 12, p. 3083, doi. 10.3390/cancers13123083
- By:
- Publication type:
- Article
Automated detection of malaria pigment: feasibility for malaria diagnosing in an area with seasonal malaria in northern Namibia.
- Published in:
- Tropical Medicine & International Health, 2006, v. 11, n. 6, p. 809, doi. 10.1111/j.1365-3156.2006.01634.x
- By:
- Publication type:
- Article
A qualitative study on the healthcare experiences of adolescents and young adults (AYA) with an uncertain or poor cancer prognosis.
- Published in:
- Supportive Care in Cancer, 2023, v. 31, n. 12, p. 1, doi. 10.1007/s00520-023-08149-9
- By:
- Publication type:
- Article
Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 1, p. 53, doi. 10.1007/s11523-021-00862-x
- By:
- Publication type:
- Article
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.
- Published in:
- British Journal of Cancer, 2018, v. 119, n. 5, p. 558, doi. 10.1038/s41416-018-0194-7
- By:
- Publication type:
- Article
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.
- Published in:
- 2018
- By:
- Publication type:
- journal article